Written by the Nuvirox Research Team
Key points
- The 10,000-step target came from the brand name of a 1965 Japanese pedometer, not from any clinical trial.
- Pooled data from 47,471 adults found mortality risk falls steeply with rising step counts, then flattens at about 6,000–8,000 steps for adults over 60 and 8,000–10,000 for younger adults.
- The relationship is observational: people who walk more may differ in many ways from people who walk less, and step counts cannot separate cause from consequence.
Short answer: fewer than you have been told, and the number depends on your age. In the largest pooled analysis available, the association between daily steps and death risk kept improving up to roughly 6,000–8,000 steps in adults over 60, and roughly 8,000–10,000 in adults under 60. Beyond those points the curve flattened. More steps were not worse — they simply stopped adding measurable benefit for this particular outcome.
Illustrative rendering of the dose–response shape reported across pooled cohorts. Curve is schematic; inflection ranges reflect the published thresholds.
Where did 10,000 steps come from?
From marketing, in the run-up to the 1964 Tokyo Olympics. A Japanese company released a pedometer called the manpo-kei — literally ‘10,000-step meter’. The figure was memorable, the character for 10,000 looks a little like a walking person, and it stuck. It was never derived from an experiment.
That does not make it a bad target. It makes it an arbitrary one. The useful question is not whether 10,000 is magic, but what the actual shape of the dose–response curve looks like — where the steep part is, and where it levels off.
What human studies actually show
The Steps for Health Collaborative pooled 15 cohorts and 47,471 adults. Participants were followed for a median of 7.1 years, during which 3,013 deaths occurred. Sorted into quartiles by daily steps — medians of about 3,553, 5,801, 7,842 and 10,901 — the three more active groups all had substantially lower mortality than the least active. Compared with the bottom quartile, adjusted hazard ratios were 0.60, 0.55 and 0.47 respectively.
The curve flattens, and where it flattens depends on age. Modelling the relationship continuously rather than in blocks showed risk falling progressively until about 6,000–8,000 steps per day in adults aged 60 and over, and until about 8,000–10,000 in adults under 60. This is the practically important result: the biggest gains come from the earliest steps, and the person going from 3,000 to 6,000 gains far more than the person going from 9,000 to 12,000.
Walking speed mattered less than total volume. After adjusting for the number of steps taken, time spent walking at faster cadences was not consistently associated with lower mortality. Some cadence measures retained significance and others did not. The signal that survived most robustly was simply how many steps happened, not how briskly.
A more recent dose–response synthesis put the practical target near 7,000. A 2025 systematic review and meta-analysis in the same journal examined a broader set of outcomes and concluded that while 10,000 steps remains a viable goal for more active people, 7,000 steps a day is associated with clinically meaningful improvements and may be a more realistic target.
The honest counterweight: every one of these studies is observational. Nobody randomised people to walk 4,000 or 9,000 steps for a decade. People who walk more tend to be healthier at baseline, and illness reduces walking long before it causes death — a problem called reverse causation that statistical adjustment reduces but cannot eliminate. The 2025 analysis also found something genuinely awkward: for incident falls in older adults, one sensitivity analysis suggested that above roughly 6,000 steps per day the association reversed direction. More exposure to walking may mean more opportunities to fall. Findings that cut against the headline deserve mentioning.
Study snapshot
| Design | Meta-analysis of 15 prospective cohorts, participant-level data |
| Participants | 47,471 adults across Asia, Australia, Europe, North America |
| Follow-up | Median 7.1 years; 3,013 deaths |
| Key finding | Risk flattens ~6,000–8,000 steps (60+) and ~8,000–10,000 (under 60) |
| Published | The Lancet Public Health, 2022 |
What a step count won’t tell you
It will not capture intensity, strength work, or anything your legs don’t do. Cycling, swimming, rowing and resistance training register poorly or not at all on a step counter, yet all contribute to the fitness and muscle mass that step counts are partly acting as a proxy for. A low step count on a day you deadlifted is not a bad day.
Step counters also disagree with each other. Wrist-worn devices tend to over-count arm movement and under-count pushing a shopping trolley or a pram; phone-based counting misses everything done while the phone is on a desk. Treat your number as a consistent personal metric rather than an absolute measurement, and compare it against your own history, not someone else’s.
If walking has become noticeably harder — breathlessness on stairs that is new, chest discomfort with exertion, leg pain that appears predictably after a set distance, or dizziness — that is a reason to see a doctor rather than a reason to push through to a target.
How should you actually use this?
Find your current baseline, then add roughly 1,000–2,000 steps. The curve is steepest at the low end, which means the person averaging 3,500 steps has more to gain from a modest increase than anyone else in the data. Chasing 10,000 from a starting point of 3,000 is a recipe for abandoning the effort in a fortnight.
Volume also appears to be the thing that accumulates, rather than any single session. Three ten-minute walks land in the same place as one thirty-minute walk as far as a step counter is concerned, and the pooled data gave no strong reason to prefer one arrangement. If you want the complementary picture on why movement produces energy rather than consuming it, we wrote about why exercise gives you energy instead of using it up. And if you are interested in what training intensity does that walking volume does not, the evidence on zone 2 training and mitochondria is a useful companion.
Frequently asked questions
Is 7,000 steps enough?
For all-cause mortality, the pooled evidence suggests most of the available association is captured by then, especially for adults over 60. A 2025 dose–response analysis specifically proposed 7,000 as a realistic and clinically meaningful target.
Do I need to walk fast for it to count?
The pooled analysis found that after accounting for total steps, faster cadence added little consistent signal for mortality. Speed may matter for fitness adaptations; it did not clearly matter for this outcome.
Does housework or pacing on the phone count?
It counts as steps and it counts as movement. The studies measured accelerometer-recorded steps during ordinary life, not deliberate exercise walks, so incidental steps are exactly what was being measured.
Is there a point where more steps become harmful?
Nothing in the mortality data suggested harm at higher counts. One fall-risk analysis in older adults did produce a signal in that direction, which is worth knowing about but is a single finding in a sensitivity analysis rather than an established result.
What about strength — does walking cover it?
No. Walking does very little to preserve muscle mass or bone density, and step counts are blind to resistance training. The two do different jobs and neither substitutes for the other. Our piece on what grip strength says about aging covers the other half of that picture.
From Nuvirox
Why we formulated NAD+ Restore
Movement is the intervention with the strongest evidence base in this whole category, and no capsule competes with it. What a supplement can reasonably do is support the cellular machinery that all that movement depends on — which is why we built ours around a precursor with published human trial data rather than a proprietary blend.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
- 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
- 10 mg galactomannans from fenugreek — to support absorption.
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Ten thousand steps was a product name that became a public health target by accident. The actual data is more forgiving and more useful: risk falls fastest at the low end, flattens somewhere between 6,000 and 10,000 depending on your age, and total volume matters more than speed. If you are currently well below that range, the most valuable steps you will ever take are the next thousand. If you are comfortably inside it, the case for grinding toward a round number is weaker than the marketing suggests.
References
- Paluch AE, Bajpai S, Bassett DR, et al. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. The Lancet Public Health. 2022;7(3):e219–e228. PMID: 35247352. DOI: 10.1016/S2468-2667(21)00302-9.
- Ding D, Nguyen B, Nau T, et al. Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis. The Lancet Public Health. 2025. DOI: 10.1016/S2468-2667(25)00164-1.
- Pontzer H, Yamada Y, Sagayama H, et al. Daily energy expenditure through the human life course. Science. 2021;373(6556):808–812. DOI: 10.1126/science.abe5017.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.
